-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Recent News from ILCN
-
In Brief for June 25, 2025
The US FDA recently granted approval to taletrectinib for ROS1-positive NSCLC and accepted a priority review for lurbinectedin plus atezolizumab for ES-SCLC in the first-line setting.
-
Lurbinectedin and Atezolizumab Combo Demonstrates Survival Benefit in ES-SCLC
Dr. Luis G. Paz-Ares reviewed new IMforte trial results at the 2025 ASCO Annual Meeting.
-
Early Data Suggest that a 14-Gene Molecular Assay May Help Predict Recurrence Risk in Patients with Early-Stage Non-Squamous NSCLC
Author Dr. David Spigel says these findings may pave the way for more accurate, biomarker-guided decisions for lung cancer treatment after surgery.
-
Rethinking Radiation: Adopting Hypofractionated Radiation Therapy
Drs. Puneeth Iyengar and Edward Christopher Dee discuss the potential clinical and environmental benefits of hypofractionated radiation therapy, along with the barriers to broader adoption.
-
Global Insights into Smoking Cessation in Lung Cancer Screening
Drs. Rachael Murray and Emma O’Dowd say despite increasing evidence that cessation efforts within screening programs are effective, a lack of clear guidance means this opportunity is often missed.
-
In Brief for June 11, 2025
VENTANA MET (SP44) RxDx Assay receives FDA approval as a companion diagnostic for telisotuzumab vedotin-tllv in patients with high c-MET overexpression in NSCLC.
-
Overcoming Resistance Remains a Challenge in Targeting KRAS
Dana-Farber’s Dr. Alice Shaw recently explored various combination strategies that show promise in preventing or delaying resistance in this previously undruggable space.
-
Immune Checkpoint Inhibitors in NSCLC: Do Survival Benefits End if Treatment Does?
Drs. Mark Awad and Federica Pecci said recent findings suggest some patients with non-small cell lung cancer may experience survival benefits and disease control even after stopping ICI treatment.
-
Falling Through the Cracks: Battling Barriers in Lung Cancer Care
California firefighter Daiyo Ito says that while the Los Angeles County wildfires brought increased health risks for his mother, the biggest obstacle to her care and treatment was navigating her lung cancer diagnosis within a broken healthcare system.
-
Research to Watch: CAN-2409 Demonstrates Survival Benefit in Patients with Advanced NSCLC Unresponsive to ICIs
According to recent phase II data, the experimental treatment demonstrated a median overall survival of 24.5 months.